Literature DB >> 25147107

Lower brain 18F-fluorodeoxyglucose uptake but normal 11C-acetoacetate metabolism in mild Alzheimer's disease dementia.

Christian-Alexandre Castellano1, Scott Nugent1, Nancy Paquet2, Sébastien Tremblay3, Christian Bocti4, Guy Lacombe5, Hélène Imbeault6, Éric Turcotte7, Tamas Fulop5, Stephen C Cunnane5.   

Abstract

BACKGROUND: The cerebral metabolic rate of glucose (CMRg) is lower in specific brain regions in Alzheimer's disease (AD). The ketones, acetoacetate and β-hydroxybutyrate, are the brain's main alternative energy substrates to glucose.
OBJECTIVE: To gain insight into brain fuel metabolism in mild AD dementia by determining whether the regional CMR and the rate constant of acetoacetate (CMRa and Ka, respectively) reflect the same metabolic deficit reported for cerebral glucose uptake (CMRg and Kg).
METHODS: Mild AD dementia (Mild AD; n = 10, age 76 y) patients were compared with gender- and age-matched cognitively normal older adults (Controls; n = 29, age 75 y) using a PET/MRI protocol and analyzed with both ROI- and voxel-based methods.
RESULTS: ROI-based analysis showed 13% lower global CMRg in the gray matter of mild AD dementia versus Controls (34.2 ± 5.0 versus 38.3 ± 4.7 μmol/100 g/min, respectively; p = 0.015), with CMRg and Kg in the parietal cortex, posterior cingulate, and thalamus being the most affected (p ≤ 0.022). Neither global nor regional CMRa or Ka differed between the two groups (all p ≥ 0.188). Voxel-based analysis showed a similar metabolic pattern to ROI-based analysis with seven clusters of significantly lower CMRg in the mild AD dementia group (uncorrected p ≤ 0.005) but with no difference in CMRa.
CONCLUSION: Regional brain energy substrate hypometabolism in mild AD dementia may be specific to impaired glucose uptake and/or utilization. This suggests a potential avenue for compensating brain energy deficit in AD dementia with ketones.

Entities:  

Keywords:  Acetoacetate; Alzheimer's disease; cerebral metabolic rate; energy metabolism; glucose; ketones; β-hydroxybutyrate

Mesh:

Substances:

Year:  2015        PMID: 25147107     DOI: 10.3233/JAD-141074

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  53 in total

1.  To Keto or Not to Keto? A Systematic Review of Randomized Controlled Trials Assessing the Effects of Ketogenic Therapy on Alzheimer Disease.

Authors:  Maria G Grammatikopoulou; Dimitrios G Goulis; Konstantinos Gkiouras; Xenophon Theodoridis; Kalliopi K Gkouskou; Athanasios Evangeliou; Efthimis Dardiotis; Dimitrios P Bogdanos
Journal:  Adv Nutr       Date:  2020-11-16       Impact factor: 8.701

2.  Automated synthesis of 1-[11C]acetoacetate on a TRASIS AIO module.

Authors:  Kiran Kumar Solingapuram Sai; H Donald Gage; Frankis Almaguel; Bryan Neth; Timothy M Hughes; Sebastien Tremblay; Christian-Alexandre Castellano; Stephen C Cunnane; Matthew J Jorgensen; Suzanne Craft; Akiva Mintz
Journal:  Appl Radiat Isot       Date:  2017-08-02       Impact factor: 1.513

3.  Very-low-calorie ketogenic diet (VLCKD) in the management of metabolic diseases: systematic review and consensus statement from the Italian Society of Endocrinology (SIE).

Authors:  M Caprio; M Infante; E Moriconi; A Armani; A Fabbri; G Mantovani; S Mariani; C Lubrano; E Poggiogalle; S Migliaccio; L M Donini; S Basciani; A Cignarelli; E Conte; G Ceccarini; F Bogazzi; L Cimino; R A Condorelli; S La Vignera; A E Calogero; A Gambineri; L Vignozzi; F Prodam; G Aimaretti; G Linsalata; S Buralli; F Monzani; A Aversa; R Vettor; F Santini; P Vitti; L Gnessi; U Pagotto; F Giorgino; A Colao; A Lenzi
Journal:  J Endocrinol Invest       Date:  2019-05-20       Impact factor: 4.256

4.  The Antiepileptic Ketogenic Diet Alters Hippocampal Transporter Levels and Reduces Adiposity in Aged Rats.

Authors:  Abbi R Hernandez; Caesar M Hernandez; Keila T Campos; Leah M Truckenbrod; Yasemin Sakarya; Joseph A McQuail; Christy S Carter; Jennifer L Bizon; Andrew P Maurer; Sara N Burke
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2018-03-14       Impact factor: 6.053

5.  Inverse relationship between brain glucose and ketone metabolism in adults during short-term moderate dietary ketosis: A dual tracer quantitative positron emission tomography study.

Authors:  Alexandre Courchesne-Loyer; Etienne Croteau; Christian-Alexandre Castellano; Valérie St-Pierre; Marie Hennebelle; Stephen C Cunnane
Journal:  J Cereb Blood Flow Metab       Date:  2016-01-01       Impact factor: 6.200

6.  Biological sex and DNA repair deficiency drive Alzheimer's disease via systemic metabolic remodeling and brain mitochondrial dysfunction.

Authors:  Tyler G Demarest; Vijay R Varma; Darlene Estrada; Mansi Babbar; Sambuddha Basu; Uma V Mahajan; Ruin Moaddel; Deborah L Croteau; Madhav Thambisetty; Mark P Mattson; Vilhelm A Bohr
Journal:  Acta Neuropathol       Date:  2020-04-24       Impact factor: 17.088

7.  Modified ketogenic diet is associated with improved cerebrospinal fluid biomarker profile, cerebral perfusion, and cerebral ketone body uptake in older adults at risk for Alzheimer's disease: a pilot study.

Authors:  Bryan J Neth; Akiva Mintz; Christopher Whitlow; Youngkyoo Jung; Kiran Solingapuram Sai; Thomas C Register; Derek Kellar; Samuel N Lockhart; Siobhan Hoscheidt; Joseph Maldjian; Amanda J Heslegrave; Kaj Blennow; Stephen C Cunnane; Christian-Alexandre Castellano; Henrik Zetterberg; Suzanne Craft
Journal:  Neurobiol Aging       Date:  2019-09-26       Impact factor: 4.673

Review 8.  Radiopharmaceuticals for Assessment of Altered Metabolism and Biometal Fluxes in Brain Aging and Alzheimer's Disease with Positron Emission Tomography.

Authors:  Fang Xie; Fangyu Peng
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

Review 9.  Neuroketotherapeutics: A modern review of a century-old therapy.

Authors:  Scott J Koppel; Russell H Swerdlow
Journal:  Neurochem Int       Date:  2017-06-01       Impact factor: 3.921

Review 10.  Ketogenic Diets for Adult Neurological Disorders.

Authors:  Tanya J W McDonald; Mackenzie C Cervenka
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.